Logo
x

Search

Subscribe Now

formycon

Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

  • July 1, 2024
The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)

The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)

  • December 27, 2023
Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

  • December 7, 2023
Insights+ Key Biosimilars Events of September 2023

Insights+ Key Biosimilars Events of September 2023

  • October 5, 2023
Formycon Reports the US FDA Acceptance of BLA for FYB203 (biosimilar, aflibercept) to Treat Retinal Diseases

Formycon Reports the US FDA Acceptance of BLA for FYB203 (biosimilar, aflibercept) to Treat Retinal Diseases

  • September 1, 2023
Formycon and Fresenius Kabi Settled with Johnson & Johnson for FYB202, a Proposed Biosimilar to Stelara (ustekinumab)

Formycon and Fresenius Kabi Settled with Johnson & Johnson for FYB202, a Proposed Biosimilar to Stelara (ustekinumab)

  • August 7, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.